Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Bennett

Interventional Cardiology Jackson, MS Medical Doctor

NPI 1760426670 CMS profile 34074

970 Lakeland Dr, Suite 61, Jackson, MS 39216

Open in the dashboard

General payments

$160,235

855 records reported · program years 2019–2025

Research payments

$5,000

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$125,779 paid to institutions, not to them · program years 2019–2025

Through program year 2025, James Bennett of Jackson, MS is reported in the CMS Open Payments database as having received $160,235 across 855 general payments and $5,000 in research payments paid to them. Separately, studies naming them as principal investigator received $125,779 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,546 101
2024 General $4,016 120
2023 General $11,168 112
2022 General $20,807 140
2021 General $34,068 144
2020 General $45,714 121
2019 General $41,916 117
2019 Research $5,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Bennett
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to James Bennett were reported at $2,546. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year James Bennett Interventional Cardiology median Middle half National median
2019 $41,916 $1,097 $329–$3,048 $163
2020 $45,714 $473 $161–$1,480 $114
2021 $34,068 $677 $233–$1,827 $132
2022 $20,807 $978 $333–$2,724 $149
2023 $11,168 $1,136 $382–$2,986 $160
2024 $4,016 $1,181 $395–$3,326 $164
2025 $2,546 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $104,162 130 payments
  2. Janssen Pharmaceuticals, Inc $27,729 50 payments
  3. Medtronic, Inc. $6,656 194 payments
  4. Medtronic Vascular, Inc. $5,952 56 payments
  5. Edwards Lifesciences Corporation $2,369 22 payments
  6. AngioDynamics, Inc. $2,322 34 payments
  7. Abbott Laboratories $2,156 32 payments
  8. Ancora Heart, Inc. $1,887 7 payments
  9. Boston Scientific Corporation $1,230 24 payments
  10. Novartis Pharmaceuticals Corporation $1,132 76 payments
  11. Other $4,641 230 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $126,556 67 payments
  2. Food and Beverage $20,210 752 payments
  3. Travel and Lodging $13,468 36 payments
Products named General payments · program years 2019–2025
  1. BRILINTA $82,731 88 payments
  2. XARELTO $27,717 49 payments
  3. FARXIGA $21,393 40 payments
  4. CoreValve Evolut Transcatheter Valve Systems $5,881 50 payments
  5. COREVALVE EVOLUT R $3,915 79 payments
  6. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $2,042 15 payments
  7. AURYON LASER SYSTEM 100-120 VAC $1,899 33 payments
  8. AccuCinch $1,887 7 payments
  9. Mitra Clip system $1,215 12 payments
  10. CoreValve Evolut Transcatheter Valve Systems $1,204 37 payments
  11. Other $11,127 476 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Philips Electronics North America Corporation $5,000 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

5,282

Median for Interventional Cardiology: 2,236

Drug cost

$779,968

Median for Interventional Cardiology: $380,412

Branded share of claims

34.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 356 $280,742
Xarelto Rivaroxaban Brand 243 $152,475
Entresto Sacubitril/Valsartan Brand 136 $109,636
Brilinta Ticagrelor Brand 192 $97,472
Repatha Sureclick Evolocumab Brand 56 $47,328
Farxiga Dapagliflozin Propanediol Brand 57 $39,032
Jardiance Empagliflozin Brand 21 $12,120
Metoprolol Succinate Generic 445 $4,943
Amiodarone Hcl Generic 88 $3,814
Clopidogrel Clopidogrel Bisulfate Brand 544 $3,706

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 100 billing codes

Paid by Medicare

$714,156

Of which drugs: $180,745

Medicare patients

1,671

Average age 76

Services billed

30,740

823 women, 848 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 66%
Arthritis 51%
Diabetes 43%
Atrial fibrillation 32%
Chronic kidney disease 29%
Heart failure 28%
Depression 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, inclisiran, 1 mg J1306 Office 33 18,744 $178,119
Injection, regadenoson, 0.1 mg J2785 Office 97 388 $2,016
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 69 6,303 $610

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
$121 — 18,744
VERQUVO
$104 — —
JARDIANCE
$74 21 —
Repatha
$62 56 —
Wegovy
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

856 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record